AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration

• Companies

• AstraZeneca PLCFollow
• Quell Therapeutics LimitedFollow

June 9 (Reuters) – AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.

UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.

Read Next

• Climate ChangecategoryWhat health experts say wildfire smoke novices need to knowJune 8, 2023
• United KingdomcategoryGSK employees to escalate strike action in June -unionJune 8, 2023
• article with videoWorldcategoryHIV alarm in Uganda as anti-gay law forces LGBT 'lockdown'June 8, 2023
• Mergers & AcquisitionscategoryNovartis' Sandoz wagers its standalone future on biosimilar successJune 8, 2023

Source reuters.com